AbCellera Biologics Inc. (ABCL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$102.1M
Cash & Equivalents
$33.5M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$2,077M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-02-01 | Phase2 Readout | — |
| 2027-04-01 | Phase1 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07118891 | Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | PHASE2 | Active Not Recruiting | 136 |
| NCT07108894 | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants | PHASE1 | Active Not Recruiting | 40 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.